Moderna (MRNA:NSD), the biotechnology company behind one of the COVID-19 vaccines, is considering a $130 price per dose in the United States, as reported by Reuters. With the transition from government to commercial market dynamics in procuring and distributing vaccines, and the pandemic emergency set to expire in May, Moderna is assessing its pricing strategy.
Moderna received almost $1.7 billion in funding for developing the vaccine and generated nearly $18 billion from its sales last year. However, contributions from COVID-19 vaccine sales to its top line have decreased.
MRNA Stock Forecast:
Based on the MRNA stock forecast from 16 analysts, the average analyst target price for Moderna Inc is USD 166.46 over the next 12 months. Moderna Inc’s average analyst rating is Hold.
Stock Target Advisor’s own stock analysis of Moderna Inc is Slightly Bullish, which is based on 10 positive signals and 5 negative signals. At the last closing, MRNA stock price was USD 154.52. Moderna Inc’s stock price has changed by +4.48% over the past week, -7.25% over the past month, and -13.64% over the last year.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.